Kemia Completes Initial Anti-Inflammatory Drug Trials
Posted on: Thursday, 24 August 2006, 15:00 CDT
Kemia has completed initial phase I clinical trials with its new anti-inflammatory drug candidate KC706. Based on the results, the company said it now plans to evaluate the compound in several diseases characterized by chronic inflammation.
Kemia believes that KC706 may hold the potential to treat conditions such as rheumatoid arthritis, psoriasis, asthma, chronic obstructive pulmonary disorder, and certain metabolic and cardiovascular diseases.
A total of 79 healthy volunteers have received KC706 to date and initial studies have shown that the drug was well tolerated. One assay conducted as part of the phase I trials confirmed that KC706 provided a long-acting, dose-dependent anti-inflammatory effect.
The first phase IIa clinical trial, treating patients suffering from rheumatoid arthritis, will commence at the end of September.
Lew Shuster, Kemia's CEO stated, "We are pleased with the clinical profile that is emerging for KC706. We will be aggressively pursuing its continued clinical development."
Source: Datamonitor
Related Articles
- New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
- Cangen Biotechnologies Inc. And Dai Nippon Printing Co., Ltd. Move Forward With Development Of An Early Stage Lung Cancer Diagnostic
- Mymetics Acquires Malaria Vaccine From Pevion
- Marshall Edwards Extends Accrual Time for Phase III Ovarian Cancer Trial
- Extended Accrual Time and Decreased Sample Size for OVATURE, a Multinational Phase III Clinical Study for Women With Recurrent Ovarian Cancer
- Antisoma Starts Phase I Clinical Trial of AS1409 in Renal Cancer and Melanoma
- deCODE Announces Positive Results From Preliminary Phase II Clinical Trial of CEP-1347 in Asthma
- VasoGenix Pharmaceuticals and Cleveland Clinic Sign Phase I/II Safety and Efficacy Clinical Trial Agreement to Develop CGRP (Calcitonin Gene Related Peptide) for Heart Failure Patients
- Pro-Pharmaceuticals to Present New DAVANAT(R) Data at the International Society of Oncodevelopmental Biology and Medicine Conference
- AVANIR Receives Special Protocol Assessment For Neurodex Neuropathic Pain Clinical Trial; Phase III Trial to Begin First Half of 2005
 |
 |
User Comments (0)
RSS Feeds